GSK China and the Home of Red Ribbon join hands to combat HIV/AIDS, unveil plan to support people living with HIV

To mark the 29th World AIDS Day, which falls on 1 December 2016, GSK China and the Home of Red Ribbon unveiled an HIV Education and Prevention Programme at a charity event themed “Hands up for HIV prevention”. The event brought together leaders from the Beijing Centre for Disease Control and Prevention, healthcare professionals (HCPs) as well as community volunteers to call for greater care, understanding, and support of people living with HIV.

HIV/AIDS is a medical condition, similar to chronic diseases such as diabetes, hypertension, and hepatitis B. In China, however, due to stigma, discrimination, and prejudice, HIV/AIDS has become a “social disease”, causing HIV sufferers to lead a life of frustration and hardship, a situation made worse by the fact that obtaining preventative care or treatments can be equally difficult. With “Hands Up for HIV Prevention” as the theme of 2016 World AIDS Day in China, HIV prevention efforts have now entered into a new phase, with prevention taking centre stage in the prevention and treatment of HIV. Controlling the spread of HIV requires the collective efforts and power of HCPs, non-profit organisations, corporates, individuals, and HIV sufferers themselves, so that more effective measures can be introduced.

With the support of GSK China, the Home of Red Ribbon has established a three year programme to address these challenges. First, roll out a self-management programme to boost sufferers’ confidence in combating the disease for the long run, and improve their ability to communicate and integrate into society. Second, by introducing a Buddy Programme, which trains volunteers through working closely with sufferers alongside the Home of Red Ribbon staff, the plan aims to enhance their knowledge and skills. This is critical in ensuring better overall care and support are provided to HIV sufferers. Third, in recent years, the rate of HIV infection among men who have sex with men (MSM) group continues to rise. This is why the plan will target both HIV positive sexual partners and HIV negative males within the group. Regular consultations and tests will be provided to enhance this group’s self protection awareness. In addition, through early detection, it can also help to decrease the overall spread of the disease.

Siaw-Fung Yap, Community Partnership Associate Director, GSK China, said, “Meeting the needs of people living with HIV, whether through medical treatment or by providing psychological care and support, has always been at the core of our AIDS prevention and treatment efforts. Thanks to the support of the Chinese government, HIV/AIDS has now become a preventable and treatable chronic disease in China. From eliminating social discrimination to providing access to innovative medications, we remain committed to addressing these issues.”

The Home of Red Ribbon is a non-profit organisation that provides integrated support and care to people living with HIV. Throughout the many years of service to these sufferers, it has accumulated a wealth of experience. Establishing a team that focuses on serving people living with HIV, the organisation sets an example in HIV/AIDS care and support in China. In addition to receiving recognition within the HIV/AIDS care community, the non-profit organisation has also drawn the attention and support from senior leaders of the Chinese government.

As part of the ‘in China, with China, for China’ strategy, GSK China has already:

  • Announced the strategic partnership with China Preventive Medicine Association (CPMA) to address major public health challenges in China in Nov 2016

  • Announced the approval of Cervarix in China to help protect women from cervical cancer in July 2016

  • Announced a Memorandum of Understanding between the GSK Institute for Infectious Diseases and Public Health and Tsinghua University to tackle global public health challenges in June 2016.

  • Launched Tivicay, an innovative HIV drug, in June 2016.

  • Participated in the national price negotiation pilot and announced a price reduction of our first line chronic hepatitis B treatment, Viread, by up to 67% in May 2016.

  • Announced a Beijing-based Institute for Infectious Disease and Public Health to conduct local development programmes for pivotal HIV and TB R&D assets in March 2016.

  • Partnered with the National Health and Family Planning Commission on a multi-year programme to fund independent training programmes in Hepatitis and COPD for over 13,000 healthcare professionals from September 2015.

  • Formalised a partnership with Shanghai-based Desano Pharmaceuticals to locally manufacture the Active Pharmaceutical Ingredient for Tivicay (dolutegravir) in July 2015.

  • Transformed our commercial operating model to actively contribute to improving the quality of scientific exchanges with healthcare professionals for the benefit of patients since May 2015.

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit

GSK commitment to China

We are a science-led global healthcare company. We research, develop and manufacture a wide range of medicines, vaccines and consumer healthcare products. People are at the heart of what we do. We strive to bring high quality, high performing products to everyone who needs them. Creating innovative products and improving access to them is critical to our mission, allowing us to help build stronger, healthier communities. In China, and around the world, we are on a mission to help people do more, feel better, live longer. We are in China, with China, for China, and our commitment remains unwavering.

GSK enquiries:

Susan Song (Shanghai)

Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2014.